Investors & Media

Nasdaq

Investor Relations

For more information and the latest news about Merus N.V., please visit our Investor Relations section by clicking the button below.

[This section of the website is under construction. You will be temporarily re-routed to Merus’ old website.] 

Investors & Media
Stock information
Nasdaq : MRUS (Common Stock)
$19.58
Change : 0.36 1.87%
Volume : 20,661
Market Cap : 443.150M
Data as of September 19, 2018 @ 04:00 pm EST
(Data provided by Nasdaq. Maximum 15 minutes delayed)
UTRECHT, The Netherlands, August 30, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company… 
– Key Oncology and Drug Development Professionals to Support Advancement of Merus’ Pipeline of… 
– MCLA-128 Phase 1/2 clinical data from the gastric cancer cohort will be presented… 
UTRECHT, The Netherlands, August 7, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company… 
– Initiation of Phase 1, first-in-human clinical trial of MCLA-158 in patients with solid… 
UTRECHT, The Netherlands, July 5, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage… 
UTRECHT, The Netherlands, May 31, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage… 
– IND Accepted in April by the U.S. FDA for MCLA-158 – UTRECHT, The… 
UTRECHT, The Netherlands, May 15, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative… 
the company's presence in 2018

Upcoming events

Are you interested in meeting the Merus team? Check out where you can find us in 2018 at (international) meetings and events.

All events
Investors & media
Investor

Downloads

Merus discovers and develops differentiated therapeutics aimed at substantially prolonging the lives of cancer patients. It is our strategy to use the power of bispecific antibody engineering and advanced screening technologies to develop biopharmaceuticals that engage the power of the immune system to kill tumor cells.

April 30, 2018
2017 ANNUAL REPORT (20-F), SEC FILING
Merus' 2017 Annual Report 20-F form, SEC filing. Registration of securities of foreign private issuers pursuant to section 12(b) or (g), filed on April 30, 2018.
August 21, 2018
August Investor Presentation
Merus Corporate Presentation - August 2018
June 15, 2017
Biopharma Dealmakers – Merus Profile
Published article "Battling Cancer with Bispecific Antibodies" in BioPharma Dealmakers, June 2017.